EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Changes in the Progression of Chronic Kidney Disease in Patients Undergoing Fecal Microbiota Transplantation

Giovanna Yazmín Arteaga-Muller iD, Samantha Flores-Treviño iD, Paola Bocanegra-Ibarias iD, Diana Robles-Espino iD, Elvira Garza-González iD, Graciela Catalina Fabela-Valdez, Adrián Camacho-Ortiz iD

Nutrients · 2024

DOI: 10.3390/nu16081109 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Nutrients, 2024. Verfasst von Giovanna Yazmín Arteaga-Muller und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, University Hospital Dr. José Eleuterio González, Autonomous University of Nuevo Leon, Monterrey 64460, Nuevo Leon, Mexico. Hauptthemen laut MEDLINE: Renal Insufficiency, Chronic, Fecal Microbiota Transplantation, Disease Progression, Gastrointestinal Microbiome. Die Arbeit wurde bisher 60-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic kidney disease (CKD) is a progressive loss of renal function in which gut dysbiosis is involved. Fecal microbiota transplantation (FMT) may be a promising alternative for restoring gut microbiota and treating CKD. This study evaluated the changes in CKD progression in patients treated with FMT. Patients with diabetes and/or hypertension with CKD clinical stages 2, 3, and 4 in this single-center, double-blind, randomized, placebo-controlled clinical trial (NCT04361097) were randomly assigned to receive either FMT or placebo capsules for 6 months. Laboratory and stool metagenomic analyses were performed. A total of 28 patients were included (15 FMT and 13 placebo). Regardless of CKD stages, patients responded similarly to FMT treatment. More patients (53.8%) from the placebo group progressed to CKD than the FMT group (13.3%). The FMT group maintained stable renal function parameters (serum creatinine and urea nitrogen) compared to the placebo group. Adverse events after FMT treatment were mild or moderate gastrointestinal symptoms. The abundance of Firmicutes and Actinobacteria decreased whereas Bacteroidetes, Proteobacteria and Roseburia spp. increased in the FMT group. CKD patients showed less disease progression after FMT administration. The administration of oral FMT in patients with CKD is a safe strategy, does not represent a risk, and has potential benefits.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Renal Insufficiency, ChronicFecal Microbiota TransplantationDisease ProgressionGastrointestinal MicrobiomeFecesHumansMaleFemaleMiddle AgedDouble-Blind MethodAgedDysbiosisTreatment OutcomeAdultCreatinine

Stichwörter der Autor:innen

chronic kidney diseasedisease progressionfecal microbiota transplant

Substanzen

Creatinine

Autor:innen und Institutionen

  • Department of Nephrology, University Hospital Dr. José Eleuterio González, Autonomous University of Nuevo Leon, Monterrey 64460, Nuevo Leon, Mexico.
  • Department of Infectious Diseases, University Hospital Dr. José Eleuterio González, Autonomous University of Nuevo Leon, Monterrey 64460, Nuevo Leon, Mexico.
  • Department of Clinical Pathology, University Hospital Dr. José Eleuterio González, Autonomous University of Nuevo Leon, Monterrey 64460, Nuevo Leon, Mexico.
  • Department of Biochemistry, School of Medicine, Autonomous University of Nuevo Leon, Monterrey 64460, Nuevo Leon, Mexico.
  • Department of Infectious Diseases and Hospital Epidemiology, University Hospital Dr. José Eleuterio González, Autonomous University of Nuevo Leon, Monterrey 64460, Nuevo Leon, Mexico.

ORCID-Profile: Giovanna Yazmín Arteaga-Muller, Samantha Flores-Treviño, Paola Bocanegra-Ibarias, Diana Robles-Espino, Elvira Garza-González, Adrián Camacho-Ortiz

Zitieren

APA

Arteaga-Muller, G. Y., Flores-Treviño, S., Bocanegra-Ibarias, P., Robles-Espino, D., Garza-González, E., Fabela-Valdez, G. C., & Camacho-Ortiz, A. (2024). Changes in the Progression of Chronic Kidney Disease in Patients Undergoing Fecal Microbiota Transplantation. Nutrients. https://doi.org/10.3390/nu16081109

Vancouver

Arteaga-Muller GY, Flores-Treviño S, Bocanegra-Ibarias P, Robles-Espino D, Garza-González E, Fabela-Valdez GC, et al. Changes in the Progression of Chronic Kidney Disease in Patients Undergoing Fecal Microbiota Transplantation. Nutrients. 2024. doi:10.3390/nu16081109

BibTeX
@article{ArteagaMuller2024,
  author = {Arteaga-Muller, Giovanna Yazmín and Flores-Treviño, Samantha and Bocanegra-Ibarias, Paola and Robles-Espino, Diana and Garza-González, Elvira and Fabela-Valdez, Graciela Catalina and Camacho-Ortiz, Adrián},
  title = {Changes in the Progression of Chronic Kidney Disease in Patients Undergoing Fecal Microbiota Transplantation},
  journal = {Nutrients},
  year = {2024},
  doi = {10.3390/nu16081109}
}
Kostenlos starten →